Global distribution agreement for RNA biomarker assays

Companies collaborate to increase accessibility of multiplex RNA assay to researchers worldwide.

Life Technologies Corporation (CA, USA) and Advanced Cell Diagnostics, Inc. (ACD; CA, USA) recently announced a global distribution agreement, stating that Life Technologies will distribute ACD’s fluorescent RNAscope^® group of probes and kits. RNAscope identifies RNA biomarkers in tissue for molecular and companion diagnostics.

“RNAscope complements our existing portfolio and solves long-standing technical hurdles researchers have encountered when studying heterogeneous samples,” commented Siddhartha Kadia, President of Life Sciences at Life Technologies. “RNAscope’s ability to provide single-molecule RNA detection, while preserving tissue context, makes it easy to pinpoint which biomarker is expressed in specific cells – all at the convenience of a conventional fluorescence microscope.”

RNAscope addresses bottlenecks, present due to lack of antibodies, and it also complements both next-generation sequencing and qPCR methods. This distribution agreement will ensure that the technology is accessible to researchers worldwide.

Yuling Luo, Founder, President and Chief Executive Officer of ACD commented on the agreement, “ACD is delighted that RNAscope products will be introduced into multiple markets through Life Technologies extensive distribution networks. Life Technologies has a legacy of introducing cutting-edge technologies to their customers and we are excited to have them represent RNAscope.”

Source: Life Technologies and Advanced Cell Diagnostics sign global distribution agreement.